SBIR Phase II

SBIR Phase II is the second stage of the U.S. Small Business Innovation Research (SBIR) program: a full research-and-development award, substantially larger and longer than a Phase I feasibility award, aimed at building and validating a prototype toward commercialization. At most participating agencies, only a business that has been awarded (and in practice has substantially completed) a Phase I award for the same R&D effort is eligible to apply for Phase II on that project — a handful of agencies run a “Direct to Phase II” exception, covered below.

What Phase II funds and how long it runs

Where Phase I asks “is this technically feasible,” Phase II funds the actual research and development: building a working prototype, generating the performance/validation data an agency, investor, or licensee will want to see, and moving the technology measurably closer to a fieldable or marketable product. Phase II performance periods are typically up to two years (24 months), longer than the roughly six-to-twelve-month Phase I stage.

Current Phase II award size

Three figures matter here, and they are not the same number:

• The statutory guideline ceiling. As of 2026, agencies may issue a Phase II award (including modifications) of up to $2,153,927 without seeking separate SBA approval — this is a program-wide ceiling set under the SBIR/STTR Policy Directive and adjusted periodically for inflation, not a typical award amount.
• SBA’s own stated norm. sbir.gov’s FAQ describes the ordinary case more conservatively: “SBIR Phase II awards normally do not exceed $1,000,000” over a period of performance of about two years. Most Phase II awards land well under the statutory ceiling; the higher figure is a cap agencies and topics can reach, not a default.
• Agency-specific figures vary. NSF, for example, states on its own SBIR/STTR site that Phase II awards are funded up to $1,250,000 for up to 24 months. Individual agencies, and even individual topics within an agency, can set their own guideline amounts below the statutory ceiling, or exceed it with an approved topic-level waiver. Because these figures are set administratively and revised periodically, verify the current cap directly against sbir.gov or the specific agency’s SBIR/STTR page before relying on a number for a live proposal.

Eligibility: the Phase I prerequisite, and Direct to Phase II

SBA’s own guidance is direct on this point: “Generally, only Phase I awardees are eligible for a Phase II award.” A firm normally cannot apply for Phase II funding on a project unless it first won (and largely completed) a Phase I feasibility award on that same technology.

A minority of agencies offer an exception. Per sbir.gov’s own program-basics guidance, a Direct to Phase II pathway is currently available at some agencies — historically including NIH, the Department of Defense, and the Department of Education — for firms that can document Phase I-equivalent feasibility results using non-SBIR funds (their own capital, prior venture investment, or published research), rather than a government-funded Phase I. NSF, by contrast, does not offer Direct to Phase II and requires the standard Phase I-to-Phase II lineage. Agency participation and rules for Direct to Phase II change between solicitation cycles, so confirm current availability directly with the specific agency’s SBIR/STTR program office before assuming a project qualifies.

Subcontracting during Phase II

SBA’s performance-of-work rule loosens between phases: a Phase I awardee must perform at least two-thirds of the research itself, but for Phase II, sbir.gov’s FAQ states the proposing firm “must perform a minimum of one-half of the research and/or analytical effort” — meaning up to roughly half of a Phase II project’s funded work can be subcontracted out. This is the structural opening that makes Phase II routinely relevant to university research administration even though a university can never itself be the SBIR awardee.

Why Phase II specifically matters for university technology transfer

The general SBIR entry covers how the program interacts with a university technology transfer office (TTO) across all three phases. Two things are specifically sharper at Phase II than at Phase I:

• IP position typically has to be more definitive by Phase II. A Phase I proposal can sometimes proceed on an early-stage option agreement or an inventor’s informal involvement. By the time a company applies for Phase II — committing an agency to a multi-year, six- or seven-figure award and asking reviewers to weigh real commercialization potential — TTOs commonly treat the Phase I-to-Phase II transition as the natural checkpoint to convert that option into a definitive exclusive license for the foundational university patent. Agency reviewers evaluating Phase II commercialization plans are looking for a secured, defined path to the IP, not an unresolved negotiation.
• University subcontracting becomes a live budget line, not a hypothetical. Because up to half of Phase II’s funded effort can be subcontracted, a common structure is for the small business to subcontract a defined portion of the Phase II R&D back to the originating university lab — often the same faculty inventor’s lab — as a paid subaward. That routes a real sponsored-research agreement through the institution’s sponsored-programs office even though the university is never the SBIR awardee itself, and it usually renews or intensifies the conflict-of-interest review of the faculty inventor’s dual role (university employee, and founder/equity holder/consultant/subcontracted researcher) that a Phase I project may not have triggered at the same scale.

Successful Phase II performance — a working prototype, validation data, sometimes early customer or investor interest — is also the evidence TTOs and licensees typically point to when negotiating the terms of the eventual Phase III commercialization license, since it demonstrates non-dilutive, peer-reviewed validation of the technology beyond the earlier feasibility stage.

Phase IIB and “bridge” awards

Some agencies — most visibly several NIH institutes, including the National Cancer Institute and the National Heart, Lung, and Blood Institute — have periodically issued supplemental funding opportunities commonly branded “Phase IIB” or “Bridge” awards, aimed at the capital-intensive gap between the end of a standard Phase II project and full commercialization (sometimes called the “Valley of Death”). These typically require a commercialization plan and evidence of committed or anticipated third-party (non-federal) investment as a matching condition. These are periodic, institute-specific funding opportunity announcements rather than a standing feature of every agency’s SBIR program — check the current NIH Guide for Grants and Contracts or the relevant agency’s SBIR/STTR solicitations for whether one is currently open before assuming a project qualifies.

Examples

• A medical-device startup completes an NIH SBIR Phase I feasibility award, then applies for and wins an NIH Phase II award (within the 2026 statutory guideline of up to $2,153,927) to build and validate a prototype toward FDA submission — subcontracting a portion of the benchtop validation work back to the university lab where the core sensor technology was originally developed, under a paid subaward negotiated through the university’s sponsored-programs office.
• An established robotics company with existing, non-SBIR-funded commercial sales applies directly for a Direct to Phase II award at an agency that offers the pathway, documenting the feasibility work it already completed with its own capital instead of first winning a separate Phase I award.

Not SBIR Phase II

• A company still finishing its Phase I feasibility work, before that award has closed out, describing its next proposal as “Phase II” before actually winning a Phase II award (or qualifying for Direct to Phase II) is describing an intention, not an actual Phase II award — eligibility and award status are separate from a company’s own labeling.
• A follow-on production contract or licensing deal funded entirely from private capital or a non-SBIR federal contract after a Phase II project ends is not Phase II — it is Phase III, which is not funded by the SBIR set-aside at all.

Frequently asked questions

Does a company have to complete Phase I before it can get a Phase II award?

Generally, yes. SBA’s own guidance states that generally only Phase I awardees are eligible for Phase II. A minority of agencies (historically including NIH, DoD, and the Department of Education) offer a Direct to Phase II exception for firms that can document Phase I-equivalent feasibility using non-SBIR funds; NSF does not offer this exception.

How much money does an SBIR Phase II award provide?

It depends on the agency and topic. The 2026 statutory guideline ceiling is $2,153,927 without separate SBA approval, but sbir.gov describes the ordinary case as normally not exceeding $1,000,000, and individual agencies set their own figures (NSF, for example, states up to $1,250,000 for up to 24 months on its own program pages). Verify the current figure directly with the awarding agency before relying on it for a specific proposal.

Can a university be a subcontractor on an SBIR Phase II award?

Yes. A university cannot be the SBIR awardee itself, but it can be a paid subcontractor. SBA rules require the small business to perform at least half of the Phase II research effort itself, leaving room to subcontract the remainder — commonly to the university lab where the underlying technology originated, structured as a standard sponsored-research subaward.

Is a Phase II award dilutive to a startup’s equity?

No. Like Phase I, an SBIR Phase II award is a grant, cooperative agreement, or contract. The federal government takes no equity and does not claim the intellectual property the award produces.

What is a Phase IIB or Bridge award?

A supplemental funding opportunity, issued periodically by some agencies (most visibly several NIH institutes), aimed at bridging the funding gap between the end of a standard Phase II project and full commercialization, typically requiring a commercialization plan and evidence of matching non-federal investment. It is not a standing feature at every agency — check current agency solicitations before assuming one is open.

References

• SBA/sbir.gov, program basics and “Additional Phase II Opportunities” tutorial — sbir.gov
• sbir.gov FAQ (award-size and performance-of-work rules)
• NSF SBIR/STTR, “Apply for Phase II” — seedfund.nsf.gov
• National Institutes of Health, SBIR Phase IIB Bridge Award funding opportunity announcements (NCI, NHLBI, NINDS; periodically issued via the NIH Guide for Grants and Contracts)
• 15 U.S.C. § 638 (Small Business Innovation Research and Small Business Technology Transfer programs)

Related terms and guides

• SBIR (Small Business Innovation Research) — the full program overview: eligibility, all three phases, and SBIR vs. STTR
• SBIR/STTR Reauthorization: Why It Lapses and What to Do — the statutory authorization risk that can pause new Phase II solicitations
• Patent Licensing — exclusive license terms TTOs negotiate with SBIR/STTR-funded spinouts
• Provisional Patent Applications — establishing the IP position a Phase II proposal typically needs secured
• Industry-University Research Partnerships — agreement structures for the subcontracted research relationship described above
• NSF I-Corps Program — customer-discovery training many SBIR/STTR applicants complete before or alongside an award
• Technology Transfer & Innovation — cluster hub